Xeris Q3 total revenue $54.3M record; guides FY to $198-$202M

Xeris Biopharma Holdings, Inc.

2024-Q3 EPS reported -$0.34 revenue$142,971,000

Product revenue $52.9M (+27% YoY); Gvoke $22.9M (+29%), Recorlev $17.7M (+119%), Keveyis $12.2M (-23%).
Net loss $15.7M ($0.11 EPS); excludes CEO succession restructuring costs of $6.1M gives adjusted EPS ($0.06).
FY 2024 total net revenue guidance raised to $198-202M from prior $190-200M; year-end cash guided to $68-72M.
Cash, cash equivalents and short-term investments $69.4M at Sept 30, 2024.
12th consecutive quarter of product revenue growth >20%; Recorlev patient count +125% YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.